Inhalers - Medical Devices Pipeline Assessment, 2017

  • ID: 4370677
  • Drug Pipelines
  • 280 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Aespira Ltd.
  • AKELA Pharma Inc.
  • Aradigm Corp
  • Bayer HealthCare AG
  • Bespak Europe Ltd
  • MORE
Inhalers - Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, “Inhalers - Medical Devices Pipeline Assessment, 2017" provides an overview of Inhalers currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Inhalers pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Inhalers under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Inhalers and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Inhalers under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Aespira Ltd.
  • AKELA Pharma Inc.
  • Aradigm Corp
  • Bayer HealthCare AG
  • Bespak Europe Ltd
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Introduction
2.1 Inhalers Overview

3. Products under Development
3.1 Inhalers - Pipeline Products by Stage of Development
3.2 Inhalers - Pipeline Products by Segment
3.3 Inhalers - Pipeline Products by Territory
3.4 Inhalers - Pipeline Products by Regulatory Path
3.5 Inhalers - Pipeline Products by Estimated Approval Date
3.6 Inhalers - Ongoing Clinical Trials

4. Inhalers - Pipeline Products under Development by Companies
4.1 Inhalers Companies - Pipeline Products by Stage of Development
4.2 Inhalers - Pipeline Products by Stage of Development

5. Inhalers Companies and Product Overview
5.1 Acorda Therapeutics Inc Company Overview
5.1.1 Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.2 Adamis Pharmaceuticals Corp Company Overview
5.2.1 Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
5.3 Advent Pharmaceuticals Pty Ltd Company Overview
5.3.1 Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.4 Aespira Ltd. Company Overview
5.4.1 Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.5 AKELA Pharma Inc. (Inactive) Company Overview
5.5.1 AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.6 Alexza Pharmaceuticals Inc Company Overview
5.6.1 Alexza Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
5.7 Aradigm Corp Company Overview
5.7.1 Aradigm Corp Pipeline Products & Ongoing Clinical Trials Overview
5.8 Bayer HealthCare AG (Inactive) Company Overview
5.8.1 Bayer HealthCare AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.9 Bellerophon Therapeutics Inc Company Overview
5.9.1 Bellerophon Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.10 Bespak Europe Ltd Company Overview
5.10.1 Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.11 Boehringer Ingelheim GmbH Company Overview
5.11.1 Boehringer Ingelheim GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.12 Circassia Pharmaceuticals Plc Company Overview
5.12.1 Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
5.13 Drexel University Company Overview
5.13.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview
5.14 FocusStart LLC Company Overview
5.14.1 FocusStart LLC Pipeline Products & Ongoing Clinical Trials Overview
5.15 GlaxoSmithKline Plc Company Overview
5.15.1 GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
5.16 MannKind Corp Company Overview
5.16.1 MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview
5.17 Medihale Ltd (Inactive) Company Overview
5.17.1 Medihale Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
5.18 Monash University Company Overview
5.18.1 Monash University Pipeline Products & Ongoing Clinical Trials Overview
5.19 Nanotherapeutics Inc Company Overview
5.19.1 Nanotherapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.20 Nektar Therapeutics Company Overview
5.20.1 Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
5.21 Nicoventures Trading Ltd Company Overview
5.21.1 Nicoventures Trading Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.22 North Carolina State University Company Overview
5.22.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
5.23 Novartis AG Company Overview
5.23.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
5.24 OPKO Health Inc Company Overview
5.24.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview
5.25 Pharmaxis Ltd Company Overview
5.25.1 Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.26 Respira Therapeutics Inc Company Overview
5.26.1 Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.27 Sandoz International GmbH Company Overview
5.27.1 Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.28 Sheffield Hallam University Company Overview
5.28.1 Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
5.29 Shin Nippon Biomedical Laboratories Ltd Company Overview
5.29.1 Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.30 Sun Pharma Advanced Research Company Ltd Company Overview
5.30.1 Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.31 Tetra Bio-Pharma Inc Company Overview
5.31.1 Tetra Bio-Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
5.32 Teva Pharmaceutical Industries Ltd Company Overview
5.32.1 Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.33 United Therapeutics Corp Company Overview
5.33.1 United Therapeutics Corp Pipeline Products & Ongoing Clinical Trials Overview
5.34 University of Kansas Company Overview
5.34.1 University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
5.35 University of Texas Medical Branch at Galveston Company Overview
5.35.1 University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
5.36 Uscom Ltd. Company Overview
5.36.1 Uscom Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.37 Vectura Group Plc Company Overview
5.37.1 Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
5.38 Verona Pharma Plc Company Overview
5.38.1 Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
5.39 Virginia Commonwealth University Company Overview
5.39.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview

6. Inhalers- Recent Developments
6.1 Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group
6.2 Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK
6.3 Jul 25, 2017: 3M Delivers Second-Quarter Sales of $7.8 Billion and Earnings of $2.58 per Share; Company Updates Its 2017 Outlook
6.4 Jul 21, 2017: GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination
6.5 Jul 21, 2017: GSK announces Board and Committee changes
6.6 Jul 19, 2017: Orion Group Half-Year Financial Report January-June 2017
6.7 Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
6.8 Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer
6.9 Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders
6.10 Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer
6.11 Jun 22, 2017: Robert J. Hennessey Appointed Chairman of the Board of Nanotherapeutics
6.12 Jun 20, 2017: Peter H. Khoury, Ph.D., MBA Appointed President and Chief Executive Officer of Nanotherapeutics
6.13 Jun 19, 2017: GSK confirms start date for Luke Miels
6.14 Jun 15, 2017: Consort Medical: Full year results
6.15 Jun 14, 2017: SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol - Fluticasone Dry Powder Inhaler (SPARC DPI)
6.16 Jun 09, 2017: Adherium Appoints New CEO to Drive Global Growth
6.17 May 25, 2017: Cipla announces Q4 & FY 17 results Continued strong performance across key markets
6.18 May 23, 2017: Novartis' new analyses reinforce the potential of Ultibro Breezhaler for COPD patients historically treated with steroids
6.19 May 23, 2017: Spiriva Respimat improves breathing for people with asthma regardless of BMI or allergic status
6.20 May 23, 2017: Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Data Showing Lung Function and Health-Related Quality of Life Improvement in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
6.21 May 17, 2017: Teva Announces Presentation on Beclomethasone Dipropionate at the 2017 American Thoracic Society (ATS) International Conference
6.22 May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk
6.23 May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk
6.24 May 15, 2017: Sunovion to Present Data on Utibron Neohaler at the American Thoracic Society 2017 International Conference
6.25 May 15, 2017: Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update
6.26 May 11, 2017: Teva Reports First Quarter 2017 Financial Results
6.27 May 10, 2017: MannKind Reports 2017 First Quarter Financial Results
6.28 May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results
6.29 May 09, 2017: Nektar Therapeutics Reports Financial Results for the First Quarter of 2017
6.30 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy
6.31 May 05, 2017: Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care
6.32 May 03, 2017: Novo Nordisk increased reported operating profit by 10% in the first three months of 2017
6.33 Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer
6.34 Apr 26, 2017: Orion Group Interim Report January-March 2017
6.35 Apr 26, 2017: GSK delivers another quarter of continued progress
6.36 Apr 26, 2017: United Therapeutics Reports First Quarter 2017 Financial Results
6.37 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
6.38 Apr 20, 2017: Teva Launches AirDuo RespiClick and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol
6.39 Apr 05, 2017: Successful financial year 2016 for Boehringer Ingelheim
6.40 Apr 04, 2017: GSK responds to Cyclone Debbie
6.41 Apr 03, 2017: Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States
6.42 Mar 31, 2017: Verona Pharma Has Developed Its First-In-Class Product Candidate RPL554 As Dry Powder Inhaler
6.43 Mar 31, 2017: Verona Pharma appoints commercial director
6.44 Mar 31, 2017: Adherium: Change to Registered Address
6.45 Mar 21, 2017: Pulmatrix Receives European Patent for its Inhaled Drug Delivery Technology
6.46 Mar 21, 2017: Vectura Group: Preliminary Results for the nine-month period ended 31 December 2016
6.47 Mar 21, 2017: Vectura Group Announces Preliminary Results for the nine-month period ended 31 December 2016
6.48 Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results
6.49 Mar 13, 2017: Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
6.50 Mar 06, 2017: Vectura Group: Board Change
6.51 Mar 03, 2017: OPKO Health Appoints Dr. Akhtar Ashfaq as Renal Division Senior Vice President, Clinical Research and Development
6.52 Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results
6.53 Mar 01, 2017: Change in Novo Nordisk Executive Management
6.54 Mar 01, 2017: Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results
6.55 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
6.56 Feb 22, 2017: United Therapeutics Reports 2016 Fourth Quarter And Annual Financial Results
6.57 Feb 22, 2017: Otsuka Pharmaceutical Certified as Excellent Health and Productivity Management Enterprise
6.58 Feb 20, 2017: Medical Developments Reports Revenue Of AUD8m In H1 Fiscal 2017
6.59 Feb 16, 2017: FDA Expands Approval of SPIRIVA RESPIMAT (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
6.60 Feb 16, 2017: Vectura achieves £9 million royalty cap from GSK Ellipta® products
6.61 Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms
6.62 Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results
6.63 Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017
6.64 Feb 08, 2017: Orion Group Financial Statement Release for 2016
6.65 Feb 08, 2017: Cipla Updates Appoints Mr. Mital Sanghvi To Senior Business Finance Role
6.66 Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016
6.67 Feb 08, 2017: Morepen labs reports yet another growth-filled quarter
6.68 Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman
6.69 Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016
6.70 Jan 30, 2017: Teva Announces FDA Approval of New AirDuo RespiClick Maintenance Inhalers for the Treatment of Asthma
6.71 Jan 30, 2017: Teva Announces FDA Approval of New ArmonAir RespiClick for the Treatment of Asthma
6.72 Jan 30, 2017: Adherium: Quarterly cash flow report to 31 December 2016
6.73 Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017
6.74 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
6.75 Jan 26, 2017: Achievement of sales milestone for COPD products
6.76 Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt
6.77 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
6.78 Jan 19, 2017: Abbas Hussain to leave GSK
6.79 Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK
6.80 Jan 18, 2017: Synchrobreathe - Cipla launches revolutionary respiratory inhaler in SA
6.81 Jan 11, 2017: Vectura Group: Pre-close update
6.82 Jan 10, 2017: Adherium appoints digital health pioneer to lead European business development
6.83 Jan 09, 2017: Cipla appoints Peter Lankau as an Independent Director on its Board
6.84 Jan 06, 2017: Teva Provides 2017 Financial Outlook
6.85 Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks
6.86 Jan 03, 2017: MannKind Receives $1 Million Milestone From RLS

7. Appendix
7.1 Methodology
7.2 About
7.3 Contact Us
7.4 Disclaimer

1.1 List of Tables
Table 1: Inhalers - Pipeline Products by Stage of Development
Table 2: Inhalers - Pipeline Products by Segment
Table 3: Inhalers - Pipeline Products by Territory
Table 4: Inhalers - Pipeline Products by Regulatory Path
Table 5: Inhalers - Pipeline Products by Estimated Approval Date
Table 6: Inhalers - Ongoing Clinical Trials
Table 7: Inhalers Companies - Pipeline Products by Stage of Development
Table 8: Inhalers - Pipeline Products by Stage of Development
Table 9: Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 10: CVT-427 Drug Delivery Device - Product Status
Table 11: CVT-427 Drug Delivery Device - Product Description
Table 12: INBRIJA - Product Status
Table 13: INBRIJA - Product Description
Table 14: PLUMIAZ Nasal Spray Device - Product Status
Table 15: PLUMIAZ Nasal Spray Device - Product Description
Table 16: Acorda Therapeutics Inc - Ongoing Clinical Trials Overview
Table 17: INBRIJA - A 12 Month, Dose-level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients with Motor Response Fluctuations (OFF Phenomena)
Table 18: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 19: Taper DPI - Product Status
Table 20: Taper DPI - Product Description
Table 21: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 22: g60 Dry Powder Inhaler - Product Status
Table 23: g60 Dry Powder Inhaler - Product Description
Table 24: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 25: resQhaler - Product Status
Table 26: resQhaler - Product Description
Table 27: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Fentanyl TAIFUN Inhaler - Product Status
Table 29: Fentanyl TAIFUN Inhaler - Product Description
Table 30: Alexza Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 31: Staccato System - Disposable Single Dose - Product Status
Table 32: Staccato System - Disposable Single Dose - Product Description
Table 33: Staccato System - Multiple Dose - Product Status
Table 34: Staccato System - Multiple Dose - Product Description
Table 35: Aradigm Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 36: Aerx Pure Nicotine Inhaler - Product Status
Table 37: Aerx Pure Nicotine Inhaler - Product Description
Table 38: Bayer HealthCare AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 39: Ciprofloxacin Dry Powder Inhaler - Product Status
Table 40: Ciprofloxacin Dry Powder Inhaler - Product Description
Table 41: Bellerophon Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 42: Mark2 Device - Product Status
Table 43: Mark2 Device - Product Description
Table 44: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 45: DEV610 DPI - Product Status
Table 46: DEV610 DPI - Product Description
Table 47: Boehringer Ingelheim GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 48: Next Generation Respimat Inhaler - Product Status
Table 49: Next Generation Respimat Inhaler - Product Description
Table 50: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 51: Tiotropium bromide DPI - Product Status
Table 52: Tiotropium bromide DPI - Product Description
Table 53: Drexel University Pipeline Products & Ongoing Clinical Trials Overview
Table 54: BREATHE Inhaler - Product Status
Table 55: BREATHE Inhaler - Product Description
Table 56: FocusStart LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 57: Smart Inhaler - Product Status
Table 58: Smart Inhaler - Product Description
Table 59: GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 60: ELLIPTA Dry Powder Inhaler - Closed Triple - Product Status
Table 61: ELLIPTA Dry Powder Inhaler - Closed Triple - Product Description
Table 62: Gemini Multi-Dose Combination Inhaler - Product Status
Table 63: Gemini Multi-Dose Combination Inhaler - Product Description
Table 64: Relvar Ellipta - Controlled Asthma - Product Status
Table 65: Relvar Ellipta - Controlled Asthma - Product Description
Table 66: GlaxoSmithKline Plc - Ongoing Clinical Trials Overview
Table 67: ELLIPTA Dry Powder Inhaler - Closed Triple - A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI with the Fixed Dose Dual Combination of FF/VI, Administered Once-daily via a Dry Powder Inhaler in Subjects with Inadequately Controlled Asthma
Table 68: ELLIPTA Dry Powder Inhaler - Closed Triple - Description of the Ability to Learn How to Handle Inhaler Devices in Asthma - AUDIT
Table 69: MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 70: Dreamboat - Product Status
Table 71: Dreamboat - Product Description
Table 72: Medihale Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
Table 73: Toucan Multi-Dose Inhaler - Product Status
Table 74: Toucan Multi-Dose Inhaler - Product Description
Table 75: Monash University Pipeline Products & Ongoing Clinical Trials Overview
Table 76: Aerosol Delivery System - Product Status
Table 77: Aerosol Delivery System - Product Description
Table 78: Nanotherapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 79: GelVac Intranasal Powder Vaccine Delivery System - Product Status
Table 80: GelVac Intranasal Powder Vaccine Delivery System - Product Description
Table 81: NanoGENT - Product Status
Table 82: NanoGENT - Product Description
Table 83: Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
Table 84: Nektar Dry Powder Inhaler - Amikacin - Product Status
Table 85: Nektar Dry Powder Inhaler - Amikacin - Product Description
Table 86: Nicoventures Trading Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 87: Nicadex Electronic Inhaler - Product Status
Table 88: Nicadex Electronic Inhaler - Product Description
Table 89: North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
Table 90: Smart Inhaler System - Product Status
Table 91: Smart Inhaler System - Product Description
Table 92: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
Table 93: Next Generation Breezhaler Inhaler - Product Status
Table 94: Next Generation Breezhaler Inhaler - Product Description
Table 95: Seebri Neohaler - Product Status
Table 96: Seebri Neohaler - Product Description
Table 97: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 98: Inspiromatic - Product Status
Table 99: Inspiromatic - Product Description
Table 100: Pharmaxis Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 101: Orbital Dry Powder Inhaler - Product Status
Table 102: Orbital Dry Powder Inhaler - Product Description
Table 103: Respira Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 104: RT234 AOS DPI - Product Status
Table 105: RT234 AOS DPI - Product Description
Table 106: Sandoz International GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 107: Solis Multi-Dose Dry Powder Inhaler - Product Status
Table 108: Solis Multi-Dose Dry Powder Inhaler - Product Description
Table 109: Unit-Dose Dry Powder Inhaler - Product Status
Table 110: Unit-Dose Dry Powder Inhaler - Product Description
Table 111: Sheffield Hallam University Pipeline Products & Ongoing Clinical Trials Overview
Table 112: Dry Powder Inhaler - Product Status
Table 113: Dry Powder Inhaler - Product Description
Table 114: Shin Nippon Biomedical Laboratories Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 115: µco System - Product Status
Table 116: µco System - Product Description
Table 117: Sun Pharma Advanced Research Company Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 118: SPARC DPI - Product Status
Table 119: SPARC DPI - Product Description
Table 120: Tetra Bio-Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 121: PPP001-Kit - Product Status
Table 122: PPP001-Kit - Product Description
Table 123: Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 124: ArmonAir RespiClick - Product Status
Table 125: ArmonAir RespiClick - Product Description
Table 126: Beclomethasone dipropionate Breath-Actuated Inhaler - Product Status
Table 127: Beclomethasone dipropionate Breath-Actuated Inhaler - Product Description
Table 128: New Inhaler Device Platform - Product Status
Table 129: New Inhaler Device Platform - Product Description
Table 130: Tidal Inhaler - Product Status
Table 131: Tidal Inhaler - Product Description
Table 132: Teva Pharmaceutical Industries Ltd - Ongoing Clinical Trials Overview
Table 133: ArmonAir RespiClick - 12-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years with Persistent Asthma
Table 134: United Therapeutics Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 135: Tyvaso-ILD - Product Status
Table 136: Tyvaso-ILD - Product Description
Table 137: University of Kansas Pipeline Products & Ongoing Clinical Trials Overview
Table 138: Dry Powder Inhaler - Product Status
Table 139: Dry Powder Inhaler - Product Description
Table 140: University of Texas Medical Branch at Galveston Pipeline Products & Ongoing Clinical Trials Overview
Table 141: Dry Powder Drug Delivery System - Product Status
Table 142: Dry Powder Drug Delivery System - Product Description
Table 143: Uscom Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 144: Spirosonic SmartSpacer - Product Status
Table 145: Spirosonic SmartSpacer - Product Description
Table 146: Vectura Group Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 147: Flutiform - COPD - Product Status
Table 148: Flutiform - COPD - Product Description
Table 149: SKP-2075 - Product Status
Table 150: SKP-2075 - Product Description
Table 151: Verona Pharma Plc Pipeline Products & Ongoing Clinical Trials Overview
Table 152: RPL554 - Dry Powder Inhaler - Product Status
Table 153: RPL554 - Dry Powder Inhaler - Product Description
Table 154: Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview
Table 155: Dry Powder Inhaler - Product Status
Table 156: Dry Powder Inhaler - Product Description
Table 157: Glossary

1.2 List of Figures
Figure 1: Inhalers - Pipeline Products by Stage of Development
Figure 2: Inhalers - Pipeline Products by Segment
Figure 3: Inhalers - Pipeline Products by Territory
Figure 4: Inhalers - Pipeline Products by Regulatory Path
Figure 5: Inhalers - Pipeline Products by Estimated Approval Date
Figure 6: Inhalers - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acorda Therapeutics Inc
  • Adamis Pharmaceuticals Corp
  • Advent Pharmaceuticals Pty Ltd
  • Aespira Ltd.
  • AKELA Pharma Inc.
  • Alexza Pharmaceuticals Inc
  • Aradigm Corp
  • Bayer HealthCare AG
  • Bellerophon Therapeutics Inc
  • Bespak Europe Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll